Ordering Recommendation

Predicts risk of dose-related toxicity to 5-FU therapy.

Mnemonic

DPYD

Methodology

Polymerase Chain Reaction/Fluorescence Monitoring

Performed

Mon, Thu

Reported

5-10 days

New York DOH Approval Status

This test is New York DOH approved.

Specimen Required

Patient Preparation
Collect

Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or serum. Heparinized specimens. Frozen specimens in glass collection tubes.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month.

Reference Interval

Interpretive Data

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81232

Components

Component Test Code* Component Chart Name LOINC
2012167 DPYD Specimen 31208-2
2013096 DPYD Genotype 45284-7
2013097 DPYD Phenotype 79719-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • 5FU drug toxicity
  • Capecitabine
  • Dihydropyrimidine
  • DPD
  • DPYD
  • DPYD genotyping
  • Fegafur
  • Uftoral
  • Xeloda
Dihydropyrimidine Dehydrogenase (DPYD), 3 Variants